[go: up one dir, main page]

ECSP11011214A - Compuestos y método de uso - Google Patents

Compuestos y método de uso

Info

Publication number
ECSP11011214A
ECSP11011214A EC2011011214A ECSP11011214A ECSP11011214A EC SP11011214 A ECSP11011214 A EC SP11011214A EC 2011011214 A EC2011011214 A EC 2011011214A EC SP11011214 A ECSP11011214 A EC SP11011214A EC SP11011214 A ECSP11011214 A EC SP11011214A
Authority
EC
Ecuador
Prior art keywords
compounds
formula
bcl
expression
present
Prior art date
Application number
EC2011011214A
Other languages
English (en)
Inventor
Danette Andrea Dudley
Steven W Elmore
Andrew J Souers
Andrew M Petros
Jonathan Bayldon Baell
Chinh Thien Bui
Peter Colman
Wayne J Fairbrother
John A Flygare
Guillaume Laurent Lessene
Chudi Ndubaku
S George Nikolakopoulos
Carl Steven Rye
Brad Edmund Sleebs
Brian John Smith
Keith Geoffrey Watson
Peter Czabotar
Original Assignee
Genentech Inc
Inst Medical W & E Hall
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Inst Medical W & E Hall, Abbott Lab filed Critical Genentech Inc
Publication of ECSP11011214A publication Critical patent/ECSP11011214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En un aspecto, la presente invención provee un compuesto de Fórmula (I) en el cual las variables X1, X2a, X2b, X2c, R1, B, L, E, A y el subíndice n son tal como se define en este texto. En otro aspecto, la presente invención provee composiciones farmacéuticas que comprenden compuestos de Fórmula (I) así como métodos para el uso de los compuestos de Fórmula (I) para el tratamiento de enfermedades y condiciones (por ejemplo, cáncer, trombocitemia, etc.) caracterizadas por la expresión o por la sobre-expresión de proteínas anti-apoptóticas Bcl-2, por ejemplo, de las proteínas anti-apoptóticas Bcl-xL.
EC2011011214A 2008-12-19 2011-07-18 Compuestos y método de uso ECSP11011214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13947908P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
ECSP11011214A true ECSP11011214A (es) 2011-09-30

Family

ID=42316717

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011214A ECSP11011214A (es) 2008-12-19 2011-07-18 Compuestos y método de uso

Country Status (21)

Country Link
US (3) US8114893B2 (es)
EP (1) EP2376085B1 (es)
JP (1) JP5683484B2 (es)
KR (1) KR101633532B1 (es)
CN (1) CN102325531B (es)
AU (1) AU2009335818A1 (es)
BR (1) BRPI0918337A2 (es)
CA (1) CA2747161C (es)
CO (1) CO6390110A2 (es)
CR (1) CR20110389A (es)
DO (1) DOP2011000198A (es)
EC (1) ECSP11011214A (es)
ES (1) ES2462715T3 (es)
IL (1) IL213547A0 (es)
MX (1) MX2011006514A (es)
NZ (1) NZ593536A (es)
PE (1) PE20120305A1 (es)
RU (1) RU2561109C2 (es)
SG (1) SG172266A1 (es)
WO (1) WO2010080478A1 (es)
ZA (1) ZA201104463B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2134685T3 (en) 2007-04-16 2015-12-07 Abbvie Inc 7-unsubstituted indole derivatives as MCL-1 inhibitors
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
AU2009335843A1 (en) * 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
PE20120305A1 (es) * 2008-12-19 2012-04-09 Abbott Lab Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
TWI561521B (en) * 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103958508B (zh) * 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
KR20140119023A (ko) 2011-12-13 2014-10-08 버크 인스티튜트 포 리서치 온 에이징 의료 요법을 개선하는 방법
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
WO2014179734A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of Michigan Deuterated amlexanox
RU2550346C2 (ru) * 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
TR201810944T4 (tr) 2013-10-25 2018-08-27 Novartis Ag Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
WO2015112801A1 (en) * 2014-01-24 2015-07-30 Purdue Pharma L.P. Pyridines and pyrimidines and use thereof
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
CN103804367B (zh) * 2014-02-28 2016-09-14 天津药物研究院 苯并氮杂卓衍生物、其制备方法和用途
WO2015153959A2 (en) 2014-04-04 2015-10-08 The Regents Of The University Of Michigan Small molecule inhibitors of mcl-1 and uses thereof
EP3708170A1 (en) 2014-05-05 2020-09-16 BioVentures, LLC Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents
WO2016007532A1 (en) * 2014-07-08 2016-01-14 Dow Agrosciences Llc Process for the preparation of 3-hydroxypicolinic acids
EP3177144A4 (en) 2014-07-22 2018-01-24 Bioventures, LLC. Compositions and methods for selectively depleting senescent cells
JP6707517B2 (ja) * 2014-07-28 2020-06-10 メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ ＧｍｂＨ 金属錯体
ES2756748T3 (es) 2014-10-03 2020-04-27 Novartis Ag Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
BR112017012342A2 (pt) * 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3407974A4 (en) 2016-01-29 2019-08-28 The Regents Of The University Of Michigan Amlexanox Analogs
NZ757763A (en) 2016-03-28 2025-07-25 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
EP3445452A4 (en) 2016-04-21 2019-10-30 BioVentures, LLC COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN108251377B (zh) * 2018-01-16 2021-08-27 内蒙古大学 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法
CN112105360B (zh) 2018-01-22 2024-01-30 生物风险投资有限责任公司 用于癌症治疗的bcl-2蛋白降解剂
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
EP3705109A1 (en) 2019-03-05 2020-09-09 Greenaltech, S.L. Carotenoids in the treatment of senescence-related diseases
WO2021213380A1 (zh) * 2020-04-20 2021-10-28 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
US20230270816A1 (en) 2020-07-06 2023-08-31 INSERM (Institute National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
IL303048A (en) 2020-11-24 2023-07-01 Novartis Ag Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物
CN118974033A (zh) * 2022-03-31 2024-11-15 百济神州有限公司 Bcl-xL抑制剂
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CR20240553A (es) 2022-05-20 2025-05-02 Servier Lab Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5265280A (en) 1975-11-26 1977-05-30 Squibb & Sons Inc Benzoxadinones and their production
DE19929785A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung
CN1422262A (zh) * 2000-02-07 2003-06-04 艾博特股份有限两合公司 2－苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
JP4403305B2 (ja) * 2001-09-03 2010-01-27 武田薬品工業株式会社 １，３−ベンゾチアジノン誘導体および用途
EP1424336A4 (en) 2001-09-03 2004-11-10 Takeda Chemical Industries Ltd 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE
CA2470721C (en) 2001-12-14 2011-07-12 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
DK2050749T3 (en) * 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
KR101511074B1 (ko) 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Ｍｃｌ-1 억제제
DK2134685T3 (en) 2007-04-16 2015-12-07 Abbvie Inc 7-unsubstituted indole derivatives as MCL-1 inhibitors
CN101842362A (zh) * 2007-09-27 2010-09-22 沃尔特及伊莱萨霍尔医学研究院 苯并噻唑化合物
EP2341052A4 (en) 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
AU2009335843A1 (en) 2008-12-19 2011-07-21 Abbvie Inc. Heterocyclic compounds and methods of use
PE20120305A1 (es) 2008-12-19 2012-04-09 Abbott Lab Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl

Also Published As

Publication number Publication date
CN102325531B (zh) 2014-04-02
EP2376085B1 (en) 2014-02-26
RU2561109C2 (ru) 2015-08-20
ES2462715T3 (es) 2014-05-26
CR20110389A (es) 2011-07-13
US20120184541A1 (en) 2012-07-19
EP2376085A1 (en) 2011-10-19
ZA201104463B (en) 2012-09-26
KR101633532B1 (ko) 2016-06-24
JP5683484B2 (ja) 2015-03-11
RU2011129789A (ru) 2013-01-27
MX2011006514A (es) 2011-10-11
CA2747161A1 (en) 2010-07-15
WO2010080478A1 (en) 2010-07-15
US8114893B2 (en) 2012-02-14
NZ593536A (en) 2013-07-26
CN102325531A (zh) 2012-01-18
CO6390110A2 (es) 2012-02-29
AU2009335818A1 (en) 2011-07-21
US20100190782A1 (en) 2010-07-29
SG172266A1 (en) 2011-07-28
IL213547A0 (en) 2011-07-31
KR20110114581A (ko) 2011-10-19
CA2747161C (en) 2017-07-18
US9067928B2 (en) 2015-06-30
US8518970B2 (en) 2013-08-27
EP2376085A4 (en) 2012-08-15
DOP2011000198A (es) 2012-08-31
JP2012512887A (ja) 2012-06-07
PE20120305A1 (es) 2012-04-09
HK1161094A1 (en) 2012-08-24
US20140005190A1 (en) 2014-01-02
BRPI0918337A2 (pt) 2017-05-30

Similar Documents

Publication Publication Date Title
ECSP11011214A (es) Compuestos y método de uso
ECSP11011213A (es) Compuestos heterocíclicos y métodos de uso
ECSP12011830A (es) Nuevos compuestos.
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
ECSP12011909A (es) Derivados de glicósido y usos de los mismos
ECSP10010434A (es) Inhibidores de hsp90
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
CU20090175A7 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
UY33199A (es) 5-alquinil-pirimidinas.
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY32009A (es) 5-alquinil-pirimidinas
ECSP11010816A (es) Nuevos Compuestos
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
UY31700A (es) Tiazolil-dihidro-indazoles
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
CO6460762A2 (es) 5-alquinil-piridinas
UY29631A1 (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
ECSP12012110A (es) 5-alquinil-pirimidinas
ECSP11011464A (es) Tia-triaza-ciclopentazulenos
CO6321260A2 (es) Derivados aromaticos de oxima como inhibidores de hsp90
ECSP12012115A (es) 5-alquinil-pirimidinas
UY29566A1 (es) "derivados de piperidina, composiciones farmaccuticas que los contienen, procedimientos de preparacinn y su uso"